JP2014507446A5 - - Google Patents

Download PDF

Info

Publication number
JP2014507446A5
JP2014507446A5 JP2013555647A JP2013555647A JP2014507446A5 JP 2014507446 A5 JP2014507446 A5 JP 2014507446A5 JP 2013555647 A JP2013555647 A JP 2013555647A JP 2013555647 A JP2013555647 A JP 2013555647A JP 2014507446 A5 JP2014507446 A5 JP 2014507446A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
following
compound
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013555647A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014507446A (ja
JP5635708B2 (ja
Filing date
Publication date
Priority claimed from US13/478,361 external-priority patent/US8426450B1/en
Application filed filed Critical
Publication of JP2014507446A publication Critical patent/JP2014507446A/ja
Publication of JP2014507446A5 publication Critical patent/JP2014507446A5/ja
Application granted granted Critical
Publication of JP5635708B2 publication Critical patent/JP5635708B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013555647A 2011-11-29 2012-11-28 Nk−1レセプター関連疾患の治療のための置換4−フェニル−ピリジン Active JP5635708B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161564537P 2011-11-29 2011-11-29
US61/564,537 2011-11-29
US13/478,361 2012-05-23
US13/478,361 US8426450B1 (en) 2011-11-29 2012-05-23 Substituted 4-phenyl pyridines having anti-emetic effect
PCT/US2012/066778 WO2013082102A1 (en) 2011-11-29 2012-11-28 Substituted 4 - phenyl - pyridines for the treatment of nk-1 receptor related diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014210716A Division JP6023146B2 (ja) 2011-11-29 2014-10-15 Nk−1レセプター関連疾患の治療のための置換4−フェニル−ピリジン

Publications (3)

Publication Number Publication Date
JP2014507446A JP2014507446A (ja) 2014-03-27
JP2014507446A5 true JP2014507446A5 (https=) 2014-06-19
JP5635708B2 JP5635708B2 (ja) 2014-12-03

Family

ID=48094815

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2013555647A Active JP5635708B2 (ja) 2011-11-29 2012-11-28 Nk−1レセプター関連疾患の治療のための置換4−フェニル−ピリジン
JP2014210716A Active JP6023146B2 (ja) 2011-11-29 2014-10-15 Nk−1レセプター関連疾患の治療のための置換4−フェニル−ピリジン
JP2016034427A Active JP6074083B2 (ja) 2011-11-29 2016-02-25 Nk−1レセプター関連疾患の治療のための置換4−フェニル−ピリジン

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2014210716A Active JP6023146B2 (ja) 2011-11-29 2014-10-15 Nk−1レセプター関連疾患の治療のための置換4−フェニル−ピリジン
JP2016034427A Active JP6074083B2 (ja) 2011-11-29 2016-02-25 Nk−1レセプター関連疾患の治療のための置換4−フェニル−ピリジン

Country Status (50)

Country Link
US (7) US8426450B1 (https=)
EP (1) EP2785706B1 (https=)
JP (3) JP5635708B2 (https=)
KR (1) KR101979050B1 (https=)
CN (6) CN111662330B (https=)
AP (1) AP2014007729A0 (https=)
AR (1) AR089019A1 (https=)
AU (1) AU2012346133B2 (https=)
BR (1) BR112014012878B1 (https=)
CA (1) CA2850644C (https=)
CL (1) CL2014001280A1 (https=)
CO (1) CO6990728A2 (https=)
CR (1) CR20140312A (https=)
CY (2) CY1118416T1 (https=)
DK (1) DK2785706T3 (https=)
DO (1) DOP2014000115A (https=)
EA (1) EA026553B1 (https=)
EC (1) ECSP14003642A (https=)
ES (1) ES2603958T3 (https=)
FI (1) FIC20200022I1 (https=)
FR (1) FR20C1029I2 (https=)
GE (1) GEP201706695B (https=)
GT (1) GT201400102A (https=)
HR (1) HRP20161708T1 (https=)
HU (2) HUE032288T2 (https=)
IL (1) IL232859B (https=)
IN (1) IN2014CN04907A (https=)
JO (1) JO3202B1 (https=)
LT (2) LT2785706T (https=)
MA (1) MA35836B1 (https=)
MD (1) MD4539C1 (https=)
ME (1) ME02561B (https=)
MX (1) MX2014006423A (https=)
MY (1) MY165514A (https=)
NI (1) NI201400043A (https=)
NL (1) NL301047I2 (https=)
PE (1) PE20141421A1 (https=)
PH (1) PH12014501199B1 (https=)
PL (1) PL2785706T3 (https=)
PT (1) PT2785706T (https=)
RS (1) RS55448B1 (https=)
SG (1) SG11201402044XA (https=)
SI (1) SI2785706T1 (https=)
SM (2) SMT201600467T1 (https=)
TN (1) TN2014000165A1 (https=)
TW (1) TWI638806B (https=)
UA (1) UA115136C2 (https=)
UY (1) UY34472A (https=)
WO (1) WO2013082102A1 (https=)
ZA (1) ZA201404787B (https=)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6250394B2 (ja) 2010-08-19 2017-12-20 バック・インスティテュート・フォー・リサーチ・オン・エイジング 軽度の認知障害(mci)および関連障害の処置方法
CN103260924B (zh) 2010-12-07 2016-11-09 艾里逊变速箱公司 用于混合动力电动车的能量存储系统
HRP20170507T1 (hr) 2011-06-22 2017-06-02 Purdue Pharma Lp Trpv1 antagonisti uključujući dihidroksi supstituente i njihove uporabe
US8426450B1 (en) 2011-11-29 2013-04-23 Helsinn Healthcare Sa Substituted 4-phenyl pyridines having anti-emetic effect
RU2673084C2 (ru) 2013-11-08 2018-11-22 Киссеи Фармасьютикал Ко., Лтд. Производное карбоксиметилпиперидина
EP3140007A1 (en) * 2014-05-05 2017-03-15 Apicore US LLC Methods of making netupitant and intermediates thereof
TWI649307B (zh) 2014-05-07 2019-02-01 日商橘生藥品工業股份有限公司 Cyclohexylpyridine derivative
TW201613888A (en) * 2014-09-26 2016-04-16 Helsinn Healthcare Sa Crystalline forms of an NK-1 antagonist
MA41051B1 (fr) 2014-10-06 2020-11-30 Vertex Pharma Modulateurs du régulateur de conductance transmembranaire de la mucoviscidose
CN105061303A (zh) * 2015-08-03 2015-11-18 成都欣捷高新技术开发有限公司 一种制备奈妥吡坦关键中间体n-甲基-4-(2-甲基苯基)-6-(4-甲基-1-哌嗪基)-3-吡啶胺的新方法
US10005803B2 (en) * 2015-10-06 2018-06-26 Helsinn Healthcare Sa Crystalline forms of fosnetupitant
CN106892864A (zh) * 2015-12-21 2017-06-27 上海科胜药物研发有限公司 一种奈妥皮坦游离碱的晶型a及其制备方法
CA3019380A1 (en) 2016-03-31 2017-10-05 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
PT3435980T (pt) * 2016-06-06 2020-02-21 Helsinn Healthcare Sa Formulações injetáveis fisiologicamente equilibradas de fosnetupitant
CN109803962B (zh) 2016-09-30 2022-04-29 弗特克斯药品有限公司 囊性纤维化跨膜传导调控蛋白的调节剂、以及药物组合物
MD3551622T2 (ro) 2016-12-09 2021-03-31 Vertex Pharma Modulator al regulatorului conductanței transmembranare în fibroză chistică, compoziții farmaceutice, metode de tratament și procedeu pentru fabricarea modulatorului
CN108619525B (zh) * 2017-03-15 2020-12-29 和龙 奈妥吡坦-mPEG-PLA纳米粒及其制备方法和用途
US11253509B2 (en) 2017-06-08 2022-02-22 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
CN121221782A (zh) 2017-06-30 2025-12-30 傲拓神经科学公司 用于治疗抑郁的nk-1拮抗剂组合物和方法
MA49631A (fr) 2017-07-17 2020-05-27 Vertex Pharma Méthodes de traitement de la fibrose kystique
JP7121794B2 (ja) 2017-08-02 2022-08-18 バーテックス ファーマシューティカルズ インコーポレイテッド ピロリジン化合物を調製するためのプロセス
CN107698500A (zh) * 2017-10-17 2018-02-16 扬子江药业集团四川海蓉药业有限公司 一种奈妥匹坦的制备方法
WO2019079760A1 (en) 2017-10-19 2019-04-25 Vertex Pharmaceuticals Incorporated CRYSTALLINE FORMS AND COMPOSITIONS OF CFTR MODULATORS
EP3720849A2 (en) 2017-12-08 2020-10-14 Vertex Pharmaceuticals Incorporated Processes for making modulators of cystic fibrosis transmembrane conductance regulator
WO2019138162A1 (en) * 2018-01-12 2019-07-18 Orion Corporation Palonosetron for the treatment or prevention of nausea and vomiting
TWI810243B (zh) 2018-02-05 2023-08-01 美商維泰克斯製藥公司 用於治療囊腫纖化症之醫藥組合物
EP3774825A1 (en) 2018-04-13 2021-02-17 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
JP7156154B2 (ja) * 2019-04-18 2022-10-19 株式会社島津製作所 培地処理システム及び培地処理方法
CN112174881B (zh) * 2019-07-04 2022-06-21 上海森辉医药有限公司 一种奈妥匹坦的衍生物及其制备方法
CN112778370B (zh) * 2019-11-06 2025-09-26 扬子江药业集团江苏海慈生物药业有限公司 一种制备福奈妥匹坦的方法
AU2021246889A1 (en) 2020-04-03 2022-10-13 Nerre Therapeutics Limited An NK-1 receptor antagonist for treating a disease selecting from sepsis, septic shock,, acute respiratory distress syndrome (ARDS) or multiple organ dysfunction syndrome (MODS)
CA3177477A1 (en) * 2020-06-02 2021-12-09 Nerre Therapeutics Limited Neurokinin (nk)-1 receptor antagonists for use in the treatment of pulmonary fibrosis conditions promoted by mechanical injury to the lungs
US12097197B2 (en) 2021-12-21 2024-09-24 Slayback Pharma Llc Stable liquid compositions of netupitant and palonosetron
WO2025036703A1 (en) 2023-08-13 2025-02-20 Helsinn Healthcare Sa Fosnetupitant for administration via intravenous bolus

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010033811A (ko) 1997-12-31 2001-04-25 토마스 안 빅토리아 2차 및 3차 아민을 함유하는 약제의 물에 용해가능한프로드럭 및 그것의 제조방법
EP1394150B1 (en) * 1999-02-24 2011-01-19 F. Hoffmann-La Roche AG 4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists
US6303790B1 (en) 1999-11-29 2001-10-16 Hoffman-La Roche Inc. Process for the preparation of pyridine derivatives
PT1103545E (pt) * 1999-11-29 2004-03-31 Hoffmann La Roche 2-(3,5-bis-trifluorometil-fenil)-n-metil-n-(6-morfolin-4-il-4-o-totil-piridin-3-il)-isobutiramida
US6362172B2 (en) * 2000-01-20 2002-03-26 Bristol-Myers Squibb Company Water soluble prodrugs of azole compounds
PT1303490E (pt) 2000-07-14 2008-09-04 Hoffmann La Roche Óxidos de aminas como pró-fármacos de antagonistas dosreceptores nk1, de derivados de 4-fenil-piridina
TWI287003B (en) * 2000-07-24 2007-09-21 Hoffmann La Roche 4-phenyl-pyridine derivatives
MXPA03005169A (es) 2000-12-14 2003-09-22 Hoffmann La Roche Matriz lipidica auto-emulsificante.
US6531597B2 (en) 2001-02-13 2003-03-11 Hoffmann-La Roche Inc. Process for preparation of 2-phenyl acetic acid derivatives
US7745625B2 (en) * 2004-03-15 2010-06-29 Bristol-Myers Squibb Company Prodrugs of piperazine and substituted piperidine antiviral agents
US20060030600A1 (en) * 2004-08-06 2006-02-09 Patrick Schnider Dual NK1/NK3 receptor antagonists for the treatment of schizophrenia
CA2602445C (en) * 2005-03-23 2013-08-20 F.Hoffmann-La Roche Ag Metabolites for nk-i antagonists for emesis
JP4981673B2 (ja) * 2005-09-13 2012-07-25 エーザイ・アール・アンド・ディー・マネジメント株式会社 安定性が改善されたクロロメチルフォスフェイト誘導体を含む組成物およびその製造方法
GB0808747D0 (en) * 2008-05-14 2008-06-18 Glaxo Wellcome Mfg Pte Ltd Novel compounds
UA108077C2 (xx) * 2009-07-02 2015-03-25 Синтез динатрієвої солі n4-(2,2-диметил-4-$(дигідрофосфонокси)метил]-3-оксо-5-піридо$1,4]оксазин-6-іл)-5-фтор-n2-(3,4,5-триметоксифеніл)-2,4-піримідиндіаміну
PT2722045T (pt) * 2009-11-18 2016-10-18 Helsinn Healthcare Sa Composições para o tratamento de náuseas e vómitos mediadas centralmente
WO2011084846A1 (en) * 2010-01-07 2011-07-14 Alkermes, Inc. Quaternary ammonium salt prodrugs
RS54766B1 (sr) * 2010-12-02 2016-10-31 Univ Kansas Prolekovi 6-cikloheksil-1-hidroksi-4-metilpiridin-2(1h)-ona i njegovih derivata
US9403772B2 (en) 2011-11-29 2016-08-02 Helsinn Healthcare Sa 4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tolyl)pyridin-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-ium as a neurokinin receptor modulator
US8426450B1 (en) 2011-11-29 2013-04-23 Helsinn Healthcare Sa Substituted 4-phenyl pyridines having anti-emetic effect
CN104718188B (zh) 2012-05-22 2018-08-21 基因泰克公司 N-取代的苯甲酰胺类及其在治疗疼痛中的用途

Similar Documents

Publication Publication Date Title
JP2014507446A5 (https=)
JP2013014622A5 (https=)
JP2012107057A5 (https=)
JP2017509667A5 (https=)
JP2009545527A5 (https=)
JP2016518337A5 (https=)
JP2015078230A5 (https=)
JP2014221779A5 (https=)
HRP20250119T1 (hr) Kdm1a inhibitor i njegova primjena u terapiji
JP2012255026A5 (https=)
JP2013525444A5 (https=)
JP2018521020A5 (https=)
JP2012126725A5 (https=)
JP2013509429A5 (https=)
JP2015501783A5 (https=)
JP2014515013A5 (https=)
JP2017008120A5 (https=)
JP2011105738A5 (https=)
JP2015528502A5 (https=)
JP2013032389A5 (https=)
JP2017537066A5 (https=)
JP2013522326A5 (https=)
EP2833721A4 (en) NICKEL OXIDE RELEASING PHARMACEUTICAL COMPOSITIONS
CL2015000578A1 (es) Compuesto n-(2-(6-fluoro-1-h-indol-3-il)etil)-3-(2,2,3,3-tetrafluoropropoxi)bencilamina o su sal, antagonista del receptor 5-ht6; composicion farmaceutica; uso en el tratamiento de la enfermedad de alzheimer.
JP2013519675A5 (https=)